secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Oncology Therapeutics, Inc. (BBOT)
CIK:        0001869105
Form:       8-K
Filed at:   2026-04-23T23:59:59+00:00
Accession:  0001193125-26-170888
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BBOT appoints Pedro Beltran as CEO, Idan Elmelech as COO, and Neil Kumar as Executive Chairman
--------------------------------------------------------------------------------

- Pedro Beltran, previously CSO, succeeds Eli Wallace as President and CEO effective April 20, 2026; also named Class III director.
- Idan Elmelech, former SVP Strategy, promoted to COO, principal financial officer; Marc Cobo becomes principal accounting officer.
- CFO Uneek Mehra departs April 30, 2026; no disagreement cited.
- Neil Kumar appointed Executive Chairman; founder figure to guide next development phase.
- Eli Wallace transitions to Senior Adviser; Board thanks him for service.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1869105/000119312526170888/0001193125-26-170888-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1869105/000119312526170888/d253464d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-170888

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer